Springer Nature, Private Bag 65901, Mairangi Bay, 0754, Auckland, New Zealand.
Drugs. 2019 Sep;79(13):1485-1494. doi: 10.1007/s40265-019-01188-9.
Selinexor (XPOVIO™) is a first-in-class, oral, small molecule Exportin-1 (XPO1) inhibitor that is being developed by Karyopharm Therapeutics for the treatment of cancer. Selinexor (in combination with dexamethasone) received accelerated approval in the USA in July 2019 for the treatment of adult patients with relapsed or refractory multiple myeloma (RRMM). Selinexor is also undergoing clinical development in a wide range of haematological and solid cancers. This article summarizes the milestones in the development of selinexor leading to this first approval for RRMM.
塞利尼索（XPOVIO™）是一种首创的、口服的、小分子的 Exportin-1（XPO1）抑制剂，由 Karyopharm Therapeutics 公司开发，用于治疗癌症。塞利尼索（与地塞米松联合使用）于 2019 年 7 月在美国获得加速批准，用于治疗复发或难治性多发性骨髓瘤（RRMM）的成年患者。塞利尼索在广泛的血液学和实体瘤癌症中也正在进行临床开发。本文总结了塞利尼索开发过程中的重要里程碑，这些里程碑导致了对 RRMM 的首次批准。
